RLS-2202

RLS-2202 (formerly RLS-2201) is a proprietary intravenous (IV) formulation of the atypical antipsychotic quetiapine, originally developed by Reliis and acquired by Patrys in 2026. It is designed for the rapid, predictable, and effective treatment of delirium and acute agitation in acute care settings, such as intensive care units (ICUs), aged care, and palliative care. By utilizing an intravenous route of administration, RLS-2202 aims to provide immediate onset of action and bypass the slow, unpredictable absorption of oral quetiapine, while also minimizing exposure to norquetiapine (the active metabolite associated with side effects like sedation and weight gain). Patrys is developing RLS-2202 via the FDA 505(b)(2) regulatory pathway, leveraging the extensive safety and efficacy data of oral quetiapine.

Other names

IV quetiapineintravenous quetiapinequetiapine intravenous